Reference : Moving from the second to the third generation Roche PTH assays: What are the consequ...
Scientific journals : Article
Human health sciences : Laboratory medicine & medical technology
http://hdl.handle.net/2268/232158
Moving from the second to the third generation Roche PTH assays: What are the consequences for clinical practice?
English
Dupuy, A. M. [Laboratoire de Biochimie et Hormonologie, CHU Montpellier, University Montpellier 1, Montpellier, France]
Bargnoux, A. S. [Laboratoire de Biochimie et Hormonologie, CHU de Montpellier, PhyMedExp, University of Montpellier, INSERM U1046, CNRS UMR 9214, Montpellier, France]
Morena, M. [Laboratoire de Biochimie et Hormonologie, CHU de Montpellier, PhyMedExp, University of Montpellier, INSERM U1046, CNRS UMR 9214, Montpellier, France]
Lauret, E. [Laboratoire de Biochimie et Hormonologie, CHU Montpellier, University Montpellier 1, Montpellier, France]
Souberbielle, J. C. [Service d'Explorations Fonctionnelles, Hôpital Necker-Enfants Malades, Assistance Publique Hôpitaux de Paris, Université René Descartes (Paris V), Paris, France]
Cavalier, Etienne mailto [Université de Liège - ULiège > Département de pharmacie > Chimie médicale >]
Cristol, J. P. [Laboratoire de Biochimie et Hormonologie, CHU Montpellier, University Montpellier 1, 371 Avenue Doyen Gaston, Giraud Montpellier, 34295, France]
Dec-2018
Clinical Chemistry and Laboratory Medicine
De Gruyter
Yes (verified by ORBi)
International
1434-6621
1437-4331
[en] PTH
[en] The determination of parathyroid hormone (PTH) is essential for exploring phosphocalcic disorders especially in patients with renal failure. At present, second or third generation PTH assays are available on the market from Roche Diagnostics as well as from others companies but the lack of standardization has complicated the interpretation. We wanted to assess the clinical impact by measuring the PTH levels with the two generations concomitantly on different groups of populations including 46 healthy, 103 pre-dialyzed and 73 hemodialyzed (HD) patients. In healthy subjects, the PTH concentrations were not different whatever the generation used, whereas beyond 200 pg/mL, we reported an overestimation of the second generation PTH. In patients with chronic kidney disease (CKD) stage 3-5 the observed differences between the two generations increase with increasing PTH levels and decreasing glomerular filtration rate (GFR). Classification according to the kidney disease: improving global outcomes (KDIGO) revealed a high percentage of discordant results between the two generations (κ coefficient <0.20). These discrepancies are clinically relevant as PTH levels remain the cornerstone for diagnosis and treatment of the CKD-mineral and bone disorder (CKD-MBD). The introduction of a new PTH assay generation in clinical practice should be carried out with caution. © 2018 Walter de Gruyter GmbH, Berlin/Boston.
http://hdl.handle.net/2268/232158
10.1515/cclm-2018-0300

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
Dupuy et al. - 2018 - Moving from the second to the third generation Roche PTH assays what are the consequences for clinical practice.pdfPublisher postprint126.92 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.